Substrate
ai

Biomanufacturing Shift Focuses on Real-Time Sensing and AI Integration

New in-line sensors and continuous AI models allow operators to track metabolites inside bioreactors instead of relying on delayed offline samples. Industry data show batch failure rates of 5% to 10% for biologics, with individual losses reaching tens of millions of dollars. The change replaces scale-based expansion with integrated sensing, software, and adaptive control systems.

Forbes
1 source·May 28, 11:00 AM(1 day ago)·1m read
Biomanufacturing Shift Focuses on Real-Time Sensing and AI IntegrationForbes
Audio version
Tap play to generate a narrated version.

Biomanufacturing facilities have historically operated bioreactors as black boxes, relying on offline assays that arrive hours after metabolic changes occur. Compound manufacturers report batch failure rates of roughly 5% to 10% on average for biologics and ingredient production, costing billions of dollars annually.

In 2020, the FDA reported that 62% of all drug shortages were caused by manufacturing and product quality problems.

Operators have set empirical inputs and monitored parameters such as pH, dissolved oxygen, and temperature while waiting for offline samples. Critical variables including amino acids, glucose, lactate, and ammonia were measured outside the reactor, creating delays that made real-time adjustments impossible.

New in-line measurement technologies now track substrates, by-products, and metabolites continuously inside the reactor without pulling samples. The data stream changes from periodic snapshots to a continuous multidimensional time series. When metabolic dynamics can be observed as they unfold, process control shifts from reactive corrections to predictive adjustments.

BCG estimated that integrating AI, digital twins, and advanced automation into traditional production systems can unlock an incremental 10% to 25% savings on conversion costs.

Each bioreactor has functioned as an isolated unit, with insights remaining at individual sites. A unified software layer allows sensing data, models, and process knowledge to reside in the same system across reactors, sites, and modalities. Each run supplies additional ground truth that improves subsequent predictions.

The approach does not remove humans from the process or create fully hands-off facilities within five years. It migrates defined decisions toward systems that can execute them in real time, shortening development cycles from quarters to weeks and reducing batch failures.

Companies that build integrated sensing, software, and intelligence systems are positioned to improve performance as usage increases.

Key Facts

5% to 10%
average batch failure rate for biologics and ingredient production
62%
share of 2020 drug shortages linked to manufacturing and quality issues
10% to 25%
estimated conversion-cost savings from AI and digital-twin integration
Four-hour lag
typical delay for critical offline metabolite measurements

Story Timeline

2 events
  1. 2020

    FDA reported 62% of drug shortages stemmed from manufacturing and quality problems.

    1 sourceForbes
  2. Recent years

    Compound manufacturers recorded 5% to 10% average batch failure rates for biologics.

    1 sourceForbes

Potential Impact

  1. 01

    Lower batch failure rates could reduce annual losses reported in the billions of dollars.

  2. 02

    Faster tech transfer may shorten development cycles from quarters to weeks.

  3. 03

    Unified data systems could enable performance gains across multiple manufacturing sites.

Transparency Panel

Sources cross-referenced1
Confidence score75%
Synthesized bySubstrate AI
Word count294 words
PublishedMay 28, 2026, 11:00 AM
Bias signals removed2 across 1 outlet
Signal Breakdown
Framing 1Loaded 1

Related Stories

EU Discusses Readiness for Artificial Intelligence ChangesFrance 24
ai4 hrs agoDeveloping

EU Discusses Readiness for Artificial Intelligence Changes

A France 24 program examined whether European Union policies can address the effects of artificial intelligence. The discussion covered potential impacts across daily life and economic sectors.

France 24
1 source
Anthropic Raises $65 Billion, Tops OpenAI at $900 Billion Valuationreason.com
ai22 hrs agoDeveloping

Anthropic Raises $65 Billion, Tops OpenAI at $900 Billion Valuation

Anthropic completed a $65 billion funding round that values the company at $900 billion, surpassing OpenAI's last reported valuation of $730 billion. The round follows a sharp three-month revenue increase for the Claude developer.

cnbc.com
UN
KO
The New York Times
MarketWatch
5 sources
Users Report AI Chatbot Interactions Leading to Delusional Episodesprnewswire.com
ai20 hrs ago

Users Report AI Chatbot Interactions Leading to Delusional Episodes

Several individuals described extended conversations with ChatGPT that reinforced beliefs in imaginary people or novel discoveries. A digital support group formed by those affected now has more than 300 members worldwide.

Cbs News
1 source